19:02 , Jan 4, 2019 |  BC Week In Review  |  Company News

BMS deal weighs on Celgene partners

The proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) on Jan. 3 put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when...
00:57 , Jan 4, 2019 |  BC Extra  |  Company News

BMS deal weighs on Celgene partners

Thursday’s proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when U.S. stocks across...
20:31 , Sep 22, 2017 |  BC Week In Review  |  Company News

Acceleron, Celgene amend sotatercept deal for pulmonary hypertension

Acceleron Pharma Inc. (NASDAQ:XLRN) gained worldwide rights to develop and commercialize sotatercept to treat pulmonary hypertension, amending a deal with partner Celgene Corp.(NASDAQ:CELG). Acceleron expects to begin a Phase II trial of sotatercept to treat...
19:56 , Sep 22, 2017 |  BC Week In Review  |  Financial News

Acceleron prices $200M follow-on

On Sept. 20, Acceleron Pharma Inc. (NASDAQ:XLRN) raised $200 million through the sale of 5.4 million shares at $37 in a bumped-up follow-on underwritten by JPMorgan, Citigroup and Leerink Partners. The price is a 5%...
19:56 , Sep 21, 2017 |  BC Extra  |  Financial News

Acceleron prices $200M follow-on

Acceleron Pharma Inc. (NASDAQ:XLRN) raised $200 million through the sale of 5.4 million shares at $37 in a bumped-up follow-on underwritten by JPMorgan, Citigroup and Leerink Partners. The price is a 5% discount to Acceleron's...
23:27 , Sep 19, 2017 |  BC Extra  |  Company News

Acceleron, Celgene amend sotatercept deal for pulmonary hypertension

Acceleron Pharma Inc. (NASDAQ:XLRN) gained worldwide rights to develop and commercialize sotatercept to treat pulmonary hypertension, amending a deal with partner Celgene Corp. (NASDAQ:CELG). Acceleron expects to begin a Phase II trial of sotatercept to...
02:21 , Oct 24, 2014 |  BC Extra  |  Top Story

Celgene boosts itself, Acceleron

Celgene Corp. (NASDAQ:CELG) added $5.64 (5.9%) to $100.40 on Thursday after reporting adjusted net income of $806 million in 3Q14, up 20% from $669 million in 3Q13, and upped its revenue and EPS guidance for...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Clinical News

Sotatercept: Additional Phase II data

Data from 22 non-transfusion dependent patients with beta thalassemia in an open-label, international Phase IIa trial showed that subcutaneous sotatercept every 3 weeks led to a maximum hemoglobin increase of >=1 g/dL above baseline in...
07:00 , Jun 23, 2014 |  BioCentury  |  Product Development

Battling beta T

Data presented at the European Hematology Association meeting this month suggest both bluebird bio Inc. and Acceleron Pharma Inc. could have the first two disease-modifying treatments for beta thalassemia. While bluebird's gene therapy approach could...
07:00 , May 5, 2014 |  BC Week In Review  |  Clinical News

Sotatercept: Additional Phase IIa data

Additional interim data from 18 evaluable patients with ESRD on hemodialysis in the 2-part, double-blind Phase IIa REN-001 trial showed that 37% of patients receiving 0.3 mg/kg subcutaneous sotatercept (n=8) and 40% of patients receiving...